Study S002409

Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Compared to Basal Insulin Start on Metabolic Targets in Patients Living With Type 2 Diabetes and Chronic Kidney Disease (Impact GLP-1 CKD)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06236672
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 348
Start: 2023-02-15
Primary completion: 2023-11-29
Lead sponsor: LMC Diabetes & Endocrinology Ltd.
Conditions: Type 2 Diabetes; Chronic Kidney Diseases
Interventions: DRUG:GLP-1 receptor agonist; DRUG:basal insulin
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

change in HbA1c (%) [baseline to 26-to-52 weeks follow-up]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004246	Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: The Impact GLP-1 CKD study. Chu L, Diabetes, obesity & metabolism	2024	Nonrandomized study	PMID 39113258 DOI	cites ClinicalTrials.gov:NCT06236672; registry reference DERIVED:39113258